Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates [PDF]
, 2017 We present the anticancer properties of cis, cis, trans-[Pt(IV)(NH3)2Cl2(OA)2] [Pt(IV)diOA] (OA = octanoato), Pt(IV) derivative of cisplatin containing two OA units appended to the axial positions of a six-coordinate Pt(IV) center.
Brabec, Viktor +8 more
core +1 more source
BMC Cancer, 2006 Background Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear.
Zhang Ping +5 more
doaj +1 more source
Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness
Thoracic Cancer, 2020 Background Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin. Although cisplatin treatment may initially be successful, its effectiveness usually reduces significantly in disease‐recurrent patients.
Maoyuan Zhao, Ting Wang, Zhouguang Hui
doaj +1 more source
Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]
, 2010 The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp +3 more
core +1 more source
Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]
, 2014 BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari +55 more
core +2 more sources
Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells [PDF]
Cells, 2019 The efficiency of cisplatin (CDDP) is significantly hindered by the development of resistance during the treatment course. To gain a detailed understanding of the molecular mechanisms underlying the development of cisplatin resistance, we comparatively analyzed established a CDDP-resistant neuroblastoma cell line (UKF-NB-4CDDP) and its susceptible ...
Miguel Angel Merlos Rodrigo +6 more
openaire +4 more sources
Frontiers in Pharmacology, 2017 Resistance to platinum-based chemotherapy is one of the most important reasons for treatment failure in advanced non-small cell lung cancer, but the underlying mechanism is extremely complex and unclear.
Aman Wang +7 more
doaj +1 more source
Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest [PDF]
, 2009 The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum drug resistance developed from H69 human small cell lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml oxaliplatin respectively. A recovery period
Davey, Ross, Stordal, Britta
core +2 more sources
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies [PDF]
, 2019 Nuclear factor E2-related factor 2 (NRF2), a transcription factor, is a master regulator of an array of genes related to oxidative and electrophilic stress that promote and maintain redox homeostasis. NRF2 function is well studied in in vitro, animal and
Deeni, Yusuf Y. +3 more
core +3 more sources
Frontiers in Cell and Developmental Biology, 2020 Cisplatin [cis-diamminedichloroplatinum (II)] is a platinum-based anticancer drug widely used for the treatment of various cancers. It forms interstrand and intrastrand cross-linking with DNA and block DNA replication, resulting in apoptosis.
Takahiro Shimizu +2 more
doaj +1 more source